北京商报讯（记者 丁宁）12月17日晚间，ST诺泰（688076）发布公告称，公司于近日收到中国证监会 下发的《行政处罚决定书》。 综合上述两项，证监会对ST诺泰责令改正，给予警告，并处以4740万元罚款；对赵德中等相关责任人 给予警告并罚款。 经查明，ST诺泰2021年年度报告存在虚假记载，公司技术转让业务不具有商业实质，不应确认收入。 该业务导致公司2021年年度报告虚增营业收入3000万元，虚增利润总额2595.16万元，占当期披露利润 总额的20.64%。 此外，ST诺泰公开发行文件编造重大虚假内容。如前所述，ST诺泰2021年虚增营业收入3000万元，虚 增利润总额2595.16万元，占当期报告记载利润总额的20.64%，其《募集说明书》中"财务会计信息"相 关内容存在重大虚假内容。 ...

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-072 江苏诺泰澳赛诺生物制药股份有限公司 关于收到《行政处罚决定书》的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"或"诺泰生物"） 于 2024 年 10 月 24 日在上海证券交易所官网（www.sse.com.cn）披露《关于公 司及实际控制人之一收到中国证券监督管理委员会立案告知书的公告》（公告编 号：2024-092），公司收到中国证券监督管理委员会（以下简称"中国证监会"） 《立案告知书》（证监立案字 0382024093 号、证监立案字 0382024094 号），因 公司涉嫌信息披露违法违规等，根据《中华人民共和国证券法》《中华人民共和 国行政处罚法》等法律法规，中国证监会决定对公司立案。 公司于 2025 年 7 月 19 日在上海证券交易所官网（www.sse.com.cn）披露《关 于收到<行政处罚事先告知书>的公告》（公告编号：2025-057），公司收到中国 证监会下发的《 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry [7] Core Insights - The medical and biological sector experienced a decline of 1.04% this week, ranking 17th among 31 primary industries [15] - The medical services sub-sector reported a closing value of 6239.94 points, with an increase of 1.67% [28] - The report highlights a shift in policy focus from cost control to quality and efficiency in the medical sector, emphasizing the need for innovation and sustainable practices [4][70] Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 31.74X, with a PB (lf) of 3.20X, showing a slight decrease from the previous week [3][36] - The top-performing companies in the medical services sector include Zhaoyan New Drug (+23.4%) and MediWest (+12.5%), while the underperformers include Guangzheng Eye Hospital (-9.4%) and Lanwei Medical (-8.7%) [2][34] Economic Policy Developments - The Central Economic Work Conference emphasized optimizing drug procurement and deepening medical insurance payment reforms, aiming to enhance the quality and efficiency of the medical industry [4][70] - The introduction of a long-term care insurance system is expected to stimulate the rehabilitation care industry and address aging population needs [11][72] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and the weight-loss drug supply chain, with specific companies like WuXi AppTec and Haoyuan Pharmaceutical highlighted [13][74] - It also points to potential recovery in profitability for third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [13][75]

Group 1 - Jinggong Technology signed a sales contract with Hubei Yuchuang worth 729 million yuan, accounting for 42.16% of the company's audited revenue for 2024 [1] - Heshun Electric is expected to win a bid for a State Grid procurement project worth 107 million yuan, representing 24.97% of the company's 2024 revenue [2] - Yongmaotai plans to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy materials [3] Group 2 - Longi Green Energy announced the termination of its plan to issue global depositary receipts abroad, stating it will not significantly impact its operations [4] - Bai Ao Intelligent is expected to win bids for projects totaling 27.5 million yuan [5] - Lian Biological is planning a change of control and asset purchase, leading to a temporary suspension of its stock [6] Group 3 - Bo Rui Communication intends to acquire 51% of Meijing Technology for 66.49 million yuan [7] - Huitai Medical plans to repurchase shares worth 200 to 250 million yuan for employee stock ownership plans [8] - Yifang Biological is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 4 - Jiuqiang Biological's shareholders signed an agreement for the transfer of 5% of the company's shares to China National Pharmaceutical Investment [11] - Songcheng Performing Arts plans to repurchase shares worth 100 to 200 million yuan for capital reduction [12] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project in Jiangxi Province [13] Group 5 - Xingfu Electronics plans to invest 480 million yuan in a new electronic-grade phosphoric acid project [14] - Jiaao Environmental Protection's stock will be subject to risk warnings due to an administrative penalty [15] - ST Nuotai received a drug registration certificate for a new injection [16] Group 6 - Haimo Technology plans to sell its controlling subsidiary, Xian Sitian Instrument, for 370 million yuan [17] - Jingce Electronics signed multiple sales contracts with a single customer totaling 433 million yuan [18] - Donghua Testing's controlling shareholder plans to reduce its stake by up to 1.99% [19][20] Group 7 - Xingqi Eye Medicine completed the first subject enrollment for a Phase II clinical trial of its eye drop product [21] - Kute Intelligent's controlling shareholder plans to reduce its stake by up to 2% [22] - Dongcheng Pharmaceutical's subsidiary received approval for a new specification of a heparin sodium injection [23] Group 8 - Zhaoyi Innovation is in the process of issuing H-shares and has received regulatory approval [24] - Aokang International's shareholder plans to reduce its stake by up to 3% [25] - Jiamei Packaging's controlling shareholder is planning a change of control, leading to a temporary stock suspension [26] Group 9 - ST Kevin's stock will have its risk warning lifted and will resume trading [27] - Zaiseng Technology's controlling shareholder plans to transfer 6.04% of the company's shares [28] - Lide New Energy's shareholder plans to reduce its stake by up to 1% [29] Group 10 - Srypu terminated its plan to acquire shares and will resume trading [30] - Longjiang Transportation's subsidiary plans to invest 2.679 billion yuan in a graphite mining project [31] - Haowei Group's controlling shareholder has not reduced its stake and has terminated the reduction plan [32] Group 11 - Huilun Crystal received an administrative penalty notice for information disclosure violations [33] - Haiguang Information terminated a major asset restructuring plan [34] - Zhongke Shuguang announced a cash dividend plan [35] Group 12 - Fushuo Technology's share purchase plan was approved by the Shenzhen Stock Exchange [36] - Dongbai Group's shareholder reduced its stake by 25.95 million shares [38]

Group 1 - The company has received the drug registration certificate for Acetate Atosiban Injection from the National Medical Products Administration, indicating successful approval for domestic production [1][3] - The drug is classified as a Class 4 chemical drug with a shelf life of 18 months and is intended for use in pregnant women with indications for preterm labor, providing a safer option with lower adverse reaction rates compared to other medications [2][3] - The approval of Acetate Atosiban Injection represents a strategic expansion for the company in the field of reproductive medicine, enhancing its market competitiveness and contributing to national population quality development [3] Group 2 - The specific sales performance of the product may be influenced by market demand and sales expansion, leading to uncertainties regarding its short-term impact on the company's operating performance [4]

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-071 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露醋酸阿托西班注射液获得 药品注册证书的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"或"诺泰生物"） 于近日收到国家药品监督管理局核准签发的醋酸阿托西班注射液的《药品注册证 书》（证书编号：2025S03644、2025S03645），现将相关情况公告如下： 一、《药品注册证书》的主要内容 药品名称：醋酸阿托西班注射液 剂型：注射剂 规格：0.9ml：6.75mg、5ml：37.5mg（按 C43H67N11O12S2计） 申请事项：药品注册（境内生产） 药品有效期：18 个月 注册分类：化学药品 4 类 包装规格：2 瓶/盒、4 瓶/盒 上市许可持有人：江苏诺泰澳赛诺生物制药股份有限公司 二、药品相关情况 醋酸阿托西班注射液是一种选择性缩宫素受体拮抗剂，可以竞争性结合子宫 肌层缩宫素受体，适用于有早产指征的妊娠妇女，用于推迟即将出现的早产。由 ...

人民财讯12月9日电，ST诺泰(688076)12月9日公告，公司于近日收到国家药监局核准签发的醋酸阿托西 班注射液的药品注册证书。醋酸阿托西班注射液适用于有早产指征的妊娠妇女，用于推迟即将出现的早 产。 ...

诺泰生物公告称，近日收到国家药监局核准签发的醋酸阿托西班注射液《药品注册证书》。药品有 0.9ml：6.75mg、5ml：37.5mg两种规格，有效期18个月，批准文号有效期至2030年。该注射液为选择性 缩宫素受体拮抗剂，适用于有早产指征的妊娠妇女。获批是公司在辅助生殖药领域的拓展，利于提升竞 争力，但产品销售受多因素影响，短期内对业绩影响不确定。 ...

Core Viewpoint - The ongoing legal case against Jiangsu Nuotai Aosaikeno Biopharmaceutical Co., Ltd. (ST Nuotai) involves allegations of false statements in securities, with investors seeking compensation for losses incurred due to these misrepresentations [1][4]. Group 1: Allegations of False Statements - Nuotai Biopharmaceutical's 2021 annual report contained false records, including a reported business income of 30 million yuan from a technology transfer to Zhejiang Huabei, which lacked the financial capability to pay for it [1][4]. - The technology transfer was deemed to lack commercial substance, leading to an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, representing 20.64% of the total profit disclosed for that period [1][4]. Group 2: Misrepresentation in Public Offering Documents - On December 12, 2023, Nuotai Biopharmaceutical issued a prospectus for a convertible bond offering of 434 million yuan, which included false financial information from the 2021 annual report [2][5]. - The prospectus disclosed that the inflated revenue and profit figures were included in the financial accounting information, constituting significant false content [2][5]. Group 3: Investor Compensation - Investors who purchased Nuotai Biopharmaceutical shares between April 28, 2022, and October 23, 2024, and still held them as of the latter date are eligible to seek compensation, subject to court verification [3][6]. - Required documentation for claims includes securities account information, stock reconciliation statements from April 1, 2022, to the present, and contact information [3][6].

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、已有案件递交立案 7月18日，诺泰生物披露收到证监会下发的《行政处罚事先告知书》，并且监管查明公司存在严重的财 务造假行为。 上海沪紫律师事务所刘鹏律师代理的案件也已陆续递交立案，等待法院审理中。根据公司业绩来看，营 收净利均增长。其前三季度实现营业收入15.27亿元，同比增长21.95%；归属净利润4.45亿元，同比增 长26.92%。（刘鹏律师专栏） 上市公司信息披露违法违规行为不仅严重扰乱证券市场秩序，更是对股民合法权益的严重侵害。根据相 关法律法规，受损投资者可提起诉讼，要求上市公司赔付损失。 索赔条件为于2022年4月28日-2024年10月23日（含当日）之前买入，并在2024年10月24日之后卖出或仍 持有而亏损的还可加入。（诺泰生物维权入口） 二、财报造假被重罚 据事先告知书，该公司2021年年报存在虚假记载，虚增营业收入300 ...